Novo Nordisk A/S — News

Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascular drug failed a late-stage clinical trial.

fool.com - 2026-07-31 16:55:01

Novo Nordisk (NYSE: NVO | NVO Price Prediction) and Eli Lilly (NYSE: LLY) both posted Q1 FY2026 results this spring, and the gap between them keeps widening.

247wallst.com - 2026-07-31 13:30:12

Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment.

fool.com - 2026-07-31 13:30:00

BioAge Labs Inc. (NASDAQ:BIOA) stock plunged Friday after disappointing Phase 3 cardiovascular trial results from Novo Nordisk A/S (NYSE:NVO) sparked concerns about the potential of NLRP3-targeting therapies.

benzinga.com - 2026-07-31 13:24:53

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced selling pressure on Friday.

investors.com - 2026-07-31 11:51:22

$30.7 billion. That's how much was cut from Novo Nordisk's market capitalization as of Friday's share price, lowering from $229.2 billion to $198.5 billion, marking a nearly 69% decline since hitting an all-time high of $635.7 billion in June 2024.

forbes.com - 2026-07-31 11:15:09

The Danish drugmaker is striving to diversify beyond its popular weight-loss drugs, but its anti-inflammatory drug candidate faces a challenge.

barrons.com - 2026-07-31 10:56:00

The Danish healthcare company's stock slumped on Friday after it announced the Phase 3 trial failure.

marketwatch.com - 2026-07-31 09:54:00

Novo Nordisk A/S (NYSE:NVO) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes trial.

benzinga.com - 2026-07-31 09:32:27

U.S.-listed shares of Novo Nordisk closed Thursday up just 1% this year. They look likely to drop into the red today.

investopedia.com - 2026-07-31 09:17:21

Novo Nordisk A/S (NYSE:NVO) is pointed sharply lower before the open after the drugmaker  said its Phase 3 trial of ziltivekimab failed to significantly reduce major adverse cardiovascular events compared to a placebo.

schaeffersresearch.com - 2026-07-31 08:31:01

Stock was down 9.5% after the company's experimental medicine ziltivekimab didn't achieve the expected risk reduction for major cardiovascular events.

wsj.com - 2026-07-31 08:02:00

Novo Nordisk shares dive 9% after heart medicine fails trial

cnbc.com - 2026-07-31 07:43:46

Novo Nordisk ​said ‌on Friday its ​experimental ​drug failed ⁠to ​reduce ​the risk of major ​cardiovascular ​events in ‌a ⁠late-stage trial involving patients ​with ​cardiovascular ⁠disease, ​chronic ​kidney ⁠disease and ⁠inflammation.

reuters.com - 2026-07-31 07:34:53

They may profit from the rapidly growing GLP-1 market in very different ways.

fool.com - 2026-07-29 16:34:00

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

zacks.com - 2026-07-29 12:41:11

Novo Nordisk shareholders allege the company misled investors about a key clinical trial for its next-generation weight-loss drug CagriSema. A U.S. judge on Tuesday allowed parts of that lawsuit to move forward.

cnbc.com - 2026-07-29 09:11:19

Amgen wants a slice of the weight loss drug market. Its candidate for capturing that market share might not be up to the task.

fool.com - 2026-07-29 07:30:00

Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.

zacks.com - 2026-07-28 18:45:47

A U.S. judge said ​on Tuesday that Novo Nordisk ‌must face part of a lawsuit accusing it of defrauding shareholders about ​a clinical trial for ​its weight loss and diabetes ⁠treatment CagriSema.

reuters.com - 2026-07-28 13:00:38

Trailing a powerful competitor, Novo Nordisk could stay firmly in second place for a good while.

fool.com - 2026-07-28 08:51:00

Novo Nordisk (NVO) is rated a Modest Buy with a raised price target of $80, driven by oral Wegovy's rapid market adoption. Oral Wegovy has achieved over 3 million prescriptions in five months, with 80% from GLP-1–naïve patients, expanding the addressable market. Sensitivity analysis suggests a base case wherein oral Wegovy could generate $12–$15 billion in annual gross profit under realistic assumptions.

seekingalpha.com - 2026-07-27 09:41:04

Novo Nordisk (NVO) has experienced a 30%+ stock decline since mid-2024, extending its ongoing downtrend. Novo Nordisk reports Q2 results next week, with investors focused less on near-term beats and more on management's confidence in transformation plans. Oral Wegovy has rapidly gained prescriptions, attracting predominantly new GLP-1 patients and expanding Novo's addressable market without materially cannibalizing established treatments.

seekingalpha.com - 2026-07-27 09:00:18

I initiate Novo Nordisk with a BUY rating and $68 price target, viewing current valuation as an attractive entry point. Oral Wegovy is expanding the treated obesity market, not just cannibalizing injectables, supported by strong prescription growth and efficacy data. Pipeline assets like high-dose Wegovy, CagriSema, and Zenagamtide offer risk-adjusted lifecycle support but face efficacy and tolerability challenges.

seekingalpha.com - 2026-07-26 21:06:05

Novo Nordisk: Mr. Market Is Pricing In Success, But It's Too Early To Bank On That

seekingalpha.com - 2026-07-26 06:05:15

Eli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy. Lilly has been winning the race to dominate the GLP-1 drug market.

fool.com - 2026-07-24 13:00:00

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

barrons.com - 2026-07-24 09:09:00

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

wsj.com - 2026-07-24 05:48:00

Novo Nordisk said on Friday it is seeking a preliminary U.S. ​court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry ​between the two groups.

reuters.com - 2026-07-24 04:41:44

With yields like this, these undervalued tickers aren't apt to remain this cheap forever.

fool.com - 2026-07-23 23:30:00

A 35-year-old institutional powerhouse just made its first move into the ETF market, betting that quality stock picking in developed markets abroad can justify a fee 23 times higher than its cheapest rival.

247wallst.com - 2026-07-23 15:41:11

MCLEAN, Va.--(BUSINESS WIRE)--Crux, a benefits operating system that connects employers, pharmaceutical manufacturers, and benefit solution providers, today announced a collaboration with global healthcare company Novo Nordisk to expand affordable and simplified access to authentic anti-obesity medications (AOMs) like Wegovy® for employer health plans across the United States. Through an alternative pharmacy benefit structure, the agreement will allow Crux to deliver a dedicated carve-out solut.

businesswire.com - 2026-07-23 09:01:00

The increasing rate of patients using GLP-1 medications is now boosting growth in Galderma's aesthetics portfolio, CEO Flemming Ørnskov told CNBC on Thursday. About 10% of U.S. adults now report taking GLP-1 drugs for weight loss, which may boost demand for treatments like fillers and anti-wrinkle injections.

cnbc.com - 2026-07-23 06:27:10

Weight loss drugs such as Mounjaro, Ozempic and Wegovy are linked to an increased risk of hair loss, according to researchers.

news.sky.com - 2026-07-22 20:57:34

Novo Nordisk (NVO) closed the most recent trading day at $48.19, moving 2.41% from the previous trading session.

zacks.com - 2026-07-22 18:46:03

PERTH, West Australia, July 22, 2026 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQB: NSRPF) is pleased to announce the release of its updated corporate presentation, now available on the Company's website. The new presentation outlines Novo's strategic priorities, exploration results, project advancements, and near-term catalysts.

globenewswire.com - 2026-07-22 16:00:00

The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.

247wallst.com - 2026-07-22 12:25:21

Novo Nordisk sues LLY over high-profile ads promoting Zepbound and Mounjaro, arguing newer clinical data changes the comparison as the GLP-1 rivalry intensifies.

zacks.com - 2026-07-22 11:46:08

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

fool.com - 2026-07-22 06:45:33

Novo Nordisk has sued rival GLP-1 drugmaker Eli Lilly in federal court, alleging misleading advertising. Novo alleges that Lilly's ads compare a lower dosage of its weight loss drug Wegovy to the highest dose of its own weight loss drug Zepbound.

fool.com - 2026-07-21 17:34:01

Novo Nordisk (NYSE:NVO) has filed a federal lawsuit against Eli Lilly, alleging that its rival's advertising campaigns for blockbuster GLP-1 obesity and diabetes drugs mislead consumers about the effectiveness of competing treatments. The complaint, filed on July 21, 2026, in the US District Court for the District of New Jersey, challenges nationwide advertisements for Lilly's Zepbound and Mounjaro that Novo claims rely on outdated clinical trial data and create an inaccurate comparison between the companies' medicines.

proactiveinvestors.com - 2026-07-21 11:24:07

LLY's leadership in obesity drugs, expanding pipeline and stronger growth outlook set it apart as investors weigh it against NVO in 2026.

zacks.com - 2026-07-21 11:20:30

Novo Nordisk alleges Eli Lilly falsely advertised Zepbound and Mounjaro by claiming the drugs outperform Wegovy and Ozempic.

barrons.com - 2026-07-21 10:29:00

Novo Nordisk A/S is suing rival drugmaker Eli Lilly & Co. for showing what it calls are misleading ads about obesity drugs in the US. Novo says Lilly is using outdated information when comparing Novo's Wegovy to Lilly's Zepbound.

youtube.com - 2026-07-21 10:21:23

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-07-21 10:02:20

Novo Nordisk (NYSE:NVO) stock is down 1% at $49.14, after the drugmaker filed a lawsuit against rival Eli Lilly (LLY), citing misleading advertising for its GLP-1 drugs.

schaeffersresearch.com - 2026-07-21 09:34:35

Ozempic drugmaker Novo Nordisk sued rival GLP-1 manufacturer Eli Lilly in federal court Tuesday, accusing the company of using “intentionally selected outdated studies” to curate allegedly misleading ad campaigns that exaggerate the efficacy of Lilly's products.

forbes.com - 2026-07-21 09:15:12

Novo Nordisk is one of the leading makers of GLP-1 weight-loss drugs. The stock has a well-above-market yield that is also well above its industry peers.

fool.com - 2026-07-21 09:15:00

Futures on the Dow Jones Industrial Average (DJI) and Nasdaq-100 Index (NDX) are comfortably higher this morning

schaeffersresearch.com - 2026-07-21 09:02:00

Novo Nordisk has filed a lawsuit against Eli Lilly (LLY) in a US federal court, accusing its rival of running false and misleading advertising campaigns for its blockbuster diabetes and weight-loss drugs. The lawsuit, filed Tuesday in the US District Court for the District of New Jersey, alleges that Eli Lilly and Lilly USA violated federal and state false advertising and unfair competition laws, including the Lanham Act.

invezz.com - 2026-07-21 08:33:37